Time to Adjuvant Chemotherapy and Its Predictors Among Women with Breast Cancer at the University of Gondar Compressive Specialized Hospital: A Retrospective Follow-Up Study

Overview

Journal Breast Cancer (Dove Med Press)

Publisher Dove Medical Press

Date 2020 Sep 28

PMID 32982398

Citations 1

Authors

Adugnaw Zeleke Alem

Ejigu Gebeye Zeleke

Temesgen Yihunie Akalu

Affiliations

Soon will be listed here.

Abstract

Background: Early adjuvant chemotherapy improves the outcomes of breast cancer patients by increasing the benefit provided by the cytotoxic systemic therapies. Despite these, the recommended time to adjuvant chemotherapy and its predictors is very limited. Therefore, this study was determining the time to adjuvant chemotherapy and its predictors among women with breast cancer at the University of Gondar Comprehensive Specialized Hospital.

Methods: An institution-based retrospective follow-up study was conducted at the University of Gondar Compressive Specialized Hospital from January 2015 to February 2019 among all women with breast cancer. Stata version 14 was used for data analysis. A stratified Cox regression model was fitted to identify the potential predictors. The adjusted hazard ratio (AHR) with a 95% confidence interval (CI) was reported to show the strength of the association. Cox-Snell residual test was used to check the goodness of fit.

Results: In this study, the median time to adjuvant chemotherapy was 67 days with an interquartile range of 34-102 days. More than three-fourth (79.9%) of patients received chemotherapy after 30 days. Of the total, 96.6% of patients with co-morbidity received adjuvant chemotherapy after 30 days. Regarding surgical complications, 97.0% of the patients with a surgical complications were received adjuvant chemotherapy after 30 days. Older patients (AHR= 0.34, 95% CI: 0.16,0.71), presence of co-morbidity (AHR= 0.43, 95% CI: 0.29, 0.62), positive surgical margin (AHR= 0.40, 95% CI: 0.25, 0.64), and presence of surgical complication (AHR= 0.55, 95% CI: 0.34, 0.88) were significantly associated with delayed time to adjuvant chemotherapy.

Conclusion: In this study, time to adjuvant chemotherapy among women was longer. Age, co-morbidity, surgical complications, and margin status were significant predictors of time to adjuvant chemotherapy. Close follow-up is important for women with surgical complications, co-morbidities, elder patients, and patients with a positive margin.

Citing Articles

Dose delay, dose reduction, and early treatment discontinuation in Black and White women receiving chemotherapy for nonmetastatic breast cancer.

Forster M, Deal A, Page A, Vohra S, Wardell A, Pak J Oncologist. 2024; 29(10):e1246-e1259.

PMID: 38913986 PMC: 11449010. DOI: 10.1093/oncolo/oyae150.

References

Lohrisch C, Paltiel C, Gelmon K, Speers C, Taylor S, Barnett J . Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2006; 24(30):4888-94. DOI: 10.1200/JCO.2005.01.6089. View

Peto R, Davies C, Godwin J, Gray R, Pan H, Clarke M . Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2011; 379(9814):432-44. PMC: 3273723. DOI: 10.1016/S0140-6736(11)61625-5. View

Wang B, Huang J, Hung W, Lin C, Lin S, Liaw Y . Impact on Survival on Interval between Surgery and Adjuvant Chemotherapy in Completely Resected Stage IB-IIIA Lung Cancer. PLoS One. 2016; 11(11):e0163809. PMC: 5115655. DOI: 10.1371/journal.pone.0163809. View

Raphael M, Biagi J, Kong W, Mates M, Booth C, Mackillop W . The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2016; 160(1):17-28. DOI: 10.1007/s10549-016-3960-3. View

Kartal M, Tezcan S, Canda T . Diagnosis, treatment characteristics, and survival of women with breast cancer aged 65 and above: a hospital-based retrospective study. BMC Womens Health. 2013; 13:34. PMC: 3765714. DOI: 10.1186/1472-6874-13-34. View

Jung S, Sereika S, Linkov F, Brufsky A, Weissfeld J, Rosenzweig M . The effect of delays in treatment for breast cancer metastasis on survival. Breast Cancer Res Treat. 2011; 130(3):953-64. DOI: 10.1007/s10549-011-1662-4. View

Yu K, Fan L, Qiu L, Ling H, Jiang Y, Shao Z . Influence of delayed initiation of adjuvant chemotherapy on breast cancer survival is subtype-dependent. Oncotarget. 2016; 8(28):46549-46556. PMC: 5542291. DOI: 10.18632/oncotarget.10551. View

Alderman A, Collins E, Schott A, Hughes M, Ottesen R, Theriault R . The impact of breast reconstruction on the delivery of chemotherapy. Cancer. 2010; 116(7):1791-800. PMC: 2847068. DOI: 10.1002/cncr.24891. View

Agarwala V, Choudhary N, Gupta S . A Risk-benefit Assessment Approach to Selection of Adjuvant Chemotherapy in Elderly Patients with Early Breast Cancer: A Mini Review. Indian J Med Paediatr Oncol. 2018; 38(4):526-534. PMC: 5759076. DOI: 10.4103/ijmpo.ijmpo_96_17. View

10.

Hershman D, Wang X, McBride R, Jacobson J, Grann V, Neugut A . Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat. 2006; 99(3):313-21. DOI: 10.1007/s10549-006-9206-z. View

11.

Alkis N, Durnali A, Arslan U, Kocer M, Onder F, Tokluoglu S . Optimal timing of adjuvant treatment in patients with early breast cancer. Med Oncol. 2010; 28(4):1255-9. DOI: 10.1007/s12032-010-9566-4. View

12.

Taplin S, Weaver S, Salas E, Chollette V, Edwards H, Bruinooge S . Reviewing cancer care team effectiveness. J Oncol Pract. 2015; 11(3):239-46. PMC: 4438110. DOI: 10.1200/JOP.2014.003350. View

13.

Maskarinec G, Pagano I, Lurie G, Bantum E, Gotay C, Issell B . Factors affecting survival among women with breast cancer in Hawaii. J Womens Health (Larchmt). 2011; 20(2):231-7. PMC: 3064877. DOI: 10.1089/jwh.2010.2114. View

14.

Gagliato D, Gonzalez-Angulo A, Lei X, Theriault R, Giordano S, Valero V . Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol. 2014; 32(8):735-44. PMC: 3940536. DOI: 10.1200/JCO.2013.49.7693. View

15.

Plotogea A, Chiarelli A, Mirea L, Prummel M, Chong N, Shumak R . Factors associated with wait times across the breast cancer treatment pathway in Ontario. Springerplus. 2013; 2:388. PMC: 3828452. DOI: 10.1186/2193-1801-2-388. View

16.

Vandergrift J, Niland J, Theriault R, Edge S, Wong Y, Loftus L . Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst. 2012; 105(2):104-12. PMC: 3611850. DOI: 10.1093/jnci/djs506. View

17.

Seneviratne S, Campbell I, Scott N, Kuper-Hommel M, Round G, Lawrenson R . Ethnic differences in timely adjuvant chemotherapy and radiation therapy for breast cancer in New Zealand: a cohort study. BMC Cancer. 2014; 14:839. PMC: 4242494. DOI: 10.1186/1471-2407-14-839. View

18.

He X, Ye F, Zhao B, Tang H, Wang J, Xiao X . Risk factors for delay of adjuvant chemotherapy in non-metastatic breast cancer patients: A systematic review and meta-analysis involving 186982 patients. PLoS One. 2017; 12(3):e0173862. PMC: 5354309. DOI: 10.1371/journal.pone.0173862. View

19.

Farolfi A, Scarpi E, Rocca A, Mangia A, Biglia N, Gianni L . Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. Eur J Cancer. 2015; 51(14):1874-81. DOI: 10.1016/j.ejca.2015.07.003. View

20.

Edge S, Compton C . The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17(6):1471-4. DOI: 10.1245/s10434-010-0985-4. View